Table 2. Prospective studies in metastatic small bowel adenocarcinoma.

Author/Publication	Study	Number of patients	Patient characteristics	Chemotherapy	Outcomes: response rates	Outcomes: median survival
Gibson et al./Oncologist 2005 (8)	Phase II, ECOG multi-institutional study	39	Locally advanced or metastatic SBA or ampullary adenocarcinoma	5-FU 600 mg/m2 (days1, 8, 29, 36), doxorubicin 30 mg/m2 (days 1, 29) & Mitomycin C 10 mg/m2 (day 1 only)	18% (n=7/39, 2 CR)	8 months
Overman et al./JCO 2009	Phase II MDACC single institution study	31	Advanced, unresectable or metastatic SBA or ampullary adenocarcinoma	Capecitabine 750 mg/m2 BID (Days 1-14) and Oxaliplatin 130 mg/m2 (day 1) every 21 days	52% (3 CR) in the 25 metastatic patients. 61% in SBA vs. 33% in ampullary adenocarcinoma	20.4 months